Phico Therapeutics is developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugsâ€. Phico's patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. SASPjectâ„¢ is a new class of antibiotic which could provide many advantages over conventional antibiotic classes. Phico Therapeutics is based at Bourn, Cambridgeshire, UK